Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADE (Bortezomib) and Rituximab in Relapsed/Refractory Indolent B-Cell Lymphoma
NCT00093769Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Aug 2004
- Primary completion
- Aug 2005
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in B-cell non-Hodgkin lymphoma (B-NHL) (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Objective Response Rate at 12 weeks. Started Aug 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT00093769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093769.